1,165
Views
3
CrossRef citations to date
0
Altmetric
Short Communication

THERPA: A small molecule database related to prion protein regulation and prion diseases progression

ORCID Icon, ORCID Icon, , , , & show all
Pages 138-142 | Received 05 Mar 2018, Accepted 30 Mar 2018, Published online: 04 May 2018

References

  • Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982 Apr 09;216(4542):136–44. doi:10.1126/science.6801762
  • Kitamoto T, Muramoto T, Mohri S, et al. Abnormal isoform of prion protein accumulates in follicular dendritic cells in mice with Creutzfeldt-Jakob disease. J Virol. 1991 Nov;65(11):6292–5.
  • Brandner S, Isenmann S, Raeber A, et al. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature. 1996 Jan 25;379(6563):339–43. doi:10.1038/379339a0
  • Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001 Jun;65(2):232–60. doi:10.1128/MMBR.65.2.232-260.2001
  • Pullman TN, Craige B, Jr., et al. Comparison of chloroquine, quinacrine (atabrine) and quinine in the treatment of acute attacks of sporozoite-induced vivax malaria, Chesson strain. J Clin Invest. 1948 May;27(3 Pt1):46–50. doi:10.1172/JCI101970
  • Giese A, Levin J, Bertsch U, et al. Effect of metal ions on de novo aggregation of full-length prion protein. Biochem Biophys Res Commun. 2004 Aug 06;320(4):1240–6. doi:10.1016/j.bbrc.2004.06.075
  • Mitteregger G, Korte S, Shakarami M, et al. Role of copper and manganese in prion disease progression. Brain Res. 2009 Oct 06;1292:155–64. doi:10.1016/j.brainres.2009.07.051
  • Doh-Ura K, Iwaki T, Caughey B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol. 2000 May;74(10):4894–7. doi:10.1128/JVI.74.10.4894-4897.2000
  • Scoazec JY, Krolak-Salmon P, Casez O, et al. Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt-Jakob disease. Ann Neurol. 2003 Apr;53(4):546–7. doi:10.1002/ana.10530
  • Sigurdsson EM, Brown DR, Alim MA, et al. Copper chelation delays the onset of prion disease. J Biol Chem. 2003 Nov 21;278(47):46199–202. doi:10.1074/jbc.C300303200
  • Hijazi N, Shaked Y, Rosenmann H, et al. Copper binding to PrPC may inhibit prion disease propagation. Brain Res. 2003 Dec 12;993(1–2):192–200. doi:10.1016/j.brainres.2003.09.014
  • Siggs OM, Cruite JT, Du X, et al. Disruption of copper homeostasis due to a mutation of Atp7a delays the onset of prion disease. Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13733–8. doi:10.1073/pnas.1211499109
  • Varela-Nallar L, Gonzalez A, Inestrosa NC. Role of copper in prion diseases: deleterious or beneficial? Curr Pharm Des. 2006;12(20):2587–95.
  • Korth C, May BC, Cohen FE, et al. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9836–41. doi:10.1073/pnas.161274798
  • Martinez-Lage JF, Rabano A, Bermejo J, et al. Creutzfeldt-Jakob disease acquired via a dural graft: failure of therapy with quinacrine and chlorpromazine. Surg Neurol. 2005 Dec;64(6):542–5. discussion 545. doi:10.1016/j.surneu.2005.03.035
  • Wroe SJ, Pal S, Siddique D, et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: A case report. Lancet. 2006 Dec 09;368(9552):2061–7. doi:10.1016/S0140-6736(06)69835-8

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.